# NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

> **NCT04211675** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nationwide Children's Hospital** · enrollment: 31 (estimated)

## Conditions studied

- Relapsed Neuroblastoma
- Refractory Neuroblastoma

## Interventions

- **BIOLOGICAL:** Natural Killer Cells
- **DRUG:** Temozolomide
- **DRUG:** Irinotecan
- **DRUG:** Dinutuximab
- **DRUG:** Sargramostim

## Key facts

- **NCT ID:** NCT04211675
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04211675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04211675, "NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04211675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*